{"id":"mylan-s-insulin-glargine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating glucose uptake in cells, inhibiting glucose production in the liver, and slowing gastric emptying. This results in a sustained decrease in blood glucose levels over a 24-hour period.","oneSentence":"Insulin glargine is a long-acting insulin analog that mimics the action of human insulin to lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:23.351Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Type 1 diabetes"}]},"trialDetails":[{"nctId":"NCT02227862","phase":"PHASE3","title":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-06","conditions":"Type 1 Diabetes","enrollment":558},{"nctId":"NCT02666430","phase":"PHASE3","title":"Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-12","conditions":"Type 1 Diabetes Mellitus","enrollment":127},{"nctId":"NCT02227875","phase":"PHASE3","title":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-08","conditions":"Type 2 Diabetes","enrollment":560}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mylan's insulin glargine","genericName":"Mylan's insulin glargine","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glargine is a long-acting insulin analog that mimics the action of human insulin to lower blood glucose levels. Used for Type 2 diabetes, Type 1 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}